Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Glaxo Consumer Has Time To Spread Wings Before Potential Solo Flight

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline will not consider spinning off of its consumer health business for two to three years, when it can evaluate its "full value," says CEO Andrew Witty. Sales of the OTC intranasal corticosteroid Flonase Allergy Relief led the firm's US consumer business sales in the latest quarter and throughout 2015.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst